TY - JOUR
T1 - Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer
AU - Sumii, Toshihiko
AU - Funakoshi, Akihiro
AU - Ito, Tetsuhide
AU - Mizumoto, Kazuhiro
AU - Tanaka, Masao
AU - Migita, Yoshikatsu
AU - Sakai, Terufumi
AU - Shinozaki, Hirotsugu
AU - Yamaguchi, Hiroya
AU - Niyahara, Toshihiko
AU - Muranaka, Toru
AU - Eriguchi, Naofumi
AU - Ueki, Toshiharu
PY - 2003/7
Y1 - 2003/7
N2 - Forty-nine patients with unresectable pancreatic cancer (stage IV disease) received gemcitabine in a multi-center trial in the Fukuoka pancreatic cancer chemotherapy group, Japan. No complete remissions, 5 partial remissions (10%) and 25 no changes (51%) were obtained. Gemcitabine could maintain QOL. Main toxicities were hematologic, especially neutropenia. Neutropenia tended to appear in early administration. Non-hematologic toxicities were anorexia, nausea/vomiting, and skin rash. The mean overall survival period was 7.5 months. Carcinomatous ascites and/or pleural effusion resulted in a poor prognosis (average survival 3.1 months). Gemcitabine could be given without severe toxicities in outpatient clinics. These results suggested that gemcitabine is currently a first-line therapeutic agent for advanced pancreatic cancer.
AB - Forty-nine patients with unresectable pancreatic cancer (stage IV disease) received gemcitabine in a multi-center trial in the Fukuoka pancreatic cancer chemotherapy group, Japan. No complete remissions, 5 partial remissions (10%) and 25 no changes (51%) were obtained. Gemcitabine could maintain QOL. Main toxicities were hematologic, especially neutropenia. Neutropenia tended to appear in early administration. Non-hematologic toxicities were anorexia, nausea/vomiting, and skin rash. The mean overall survival period was 7.5 months. Carcinomatous ascites and/or pleural effusion resulted in a poor prognosis (average survival 3.1 months). Gemcitabine could be given without severe toxicities in outpatient clinics. These results suggested that gemcitabine is currently a first-line therapeutic agent for advanced pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=0043246770&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0043246770&partnerID=8YFLogxK
M3 - Article
C2 - 12894712
AN - SCOPUS:0043246770
SN - 0385-0684
VL - 30
SP - 971
EP - 976
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 7
ER -
